TegoScience Inc
TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services. The company was founded in 2001 and is based in Seoul, South Korea.
TegoScience Inc (191420) - Total Liabilities
Latest total liabilities as of September 2025: ₩24.79 Billion KRW
Based on the latest financial reports, TegoScience Inc (191420) has total liabilities worth ₩24.79 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
TegoScience Inc - Total Liabilities Trend (2015–2024)
This chart illustrates how TegoScience Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
TegoScience Inc Competitors by Total Liabilities
The table below lists competitors of TegoScience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shougang Concord Century Holdings Limited
F:CW7
|
Germany | €1.80 Billion |
|
Cementos Bio-B
SN:CEMENTOS
|
Chile | CL$239.33 Billion |
|
RoyalTek Co Ltd
TWO:3306
|
Taiwan | NT$470.54 Million |
|
Cato Corporation
NYSE:CATO
|
USA | $282.59 Million |
|
Jinxin Technology Holding Company American Depositary Shares
NASDAQ:NAMI
|
USA | $91.95 Million |
|
STEP Energy Services Ltd
PINK:SNVVF
|
USA | $142.07 Million |
|
Nature Holdings Co. Ltd.
KQ:298540
|
Korea | ₩290.44 Billion |
|
SDN Company. Ltd
KQ:099220
|
Korea | ₩79.30 Billion |
Liability Composition Analysis (2015–2024)
This chart breaks down TegoScience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 27.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how TegoScience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for TegoScience Inc (2015–2024)
The table below shows the annual total liabilities of TegoScience Inc from 2015 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩2.66 Billion | +2.74% |
| 2023-12-31 | ₩2.58 Billion | -6.57% |
| 2022-12-31 | ₩2.77 Billion | +9.37% |
| 2021-12-31 | ₩2.53 Billion | +78.99% |
| 2020-12-31 | ₩1.41 Billion | +88.26% |
| 2019-12-31 | ₩750.71 Million | -14.89% |
| 2018-12-31 | ₩882.02 Million | -92.57% |
| 2017-12-31 | ₩11.87 Billion | -36.38% |
| 2016-12-31 | ₩18.66 Billion | +3282.24% |
| 2015-12-31 | ₩551.82 Million | -- |